Enhancing Drug Performance Through Lipid-Based Formulations for CNS Indication
Summary: A clinical-stage biopharmaceutical company was developing a potent and highly selective inhibitor of Bruton Tyrosine Kinase (BTK) to treat hematologic malignancies with central nervous system (CNS) involvement. This first-in-class molecule was orally administered and able to penetrate the blood-brain barrier representing a significant advancement in disease treatment. To address the challenges of low bioavailability, variability in drug exposure, and Active Pharmaceutical Ingredient (API) instability, the company engaged with ÌìÃÀÓ°Ôº to develop an oral lipid-based formulation that would lead to a more predictable and reliable drug response.​